Author: UW CTI

As one dives into the annals of cancer research history, the astounding pace of drug discovery and development, coupled with the emergence of multimodal and multidisciplinary innovations, evokes a sense of wonder....

Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer....

Clinical trials represent a critical path to innovative treatments, life-changing cures, and medical progress. But for all their scientific rigor, most trials fail to include one crucial element: input from the very people they aim to help....

After more than a decade studying a rare eye cancer that produces some of the hardest-to-fight tumors, researchers from University of Pittsburgh Medical Center have found a treatment that works on some patients and, more importantly, a tool that can predict when it is likely...